Piramal Pharma Solutions

New Publication | Advancing the Science of ADC Manufacturing

As antibody-drug conjugates (ADCs) continue to transform targeted therapeutics, successful development requires more than scientific innovation. It demands the right manufacturing strategy and partnerships.

We're proud to share a new publication by our ADC expert and member of our Science Collective Conor Barry, "The Role of Contract Manufacturing in Antibody–Drug Conjugate (ADC) Drug Substance Development – Strategies for Successful Engagement," published in AAPS Pharm SciTech.

The article explores how strategic CDMO engagement, technology transfer, process scalability and integrated supply chain planning can help accelerate ADC development from early clinical stages through commercial manufacturing.

Read the publication here: https://lnkd.in/djk4r_D7
You can also checkout the publication on: https://lnkd.in/djk4r_D7

As drug discovery and development become increasingly complex, bioanalytical services play a vital role in generating the precise data needed to guide critical decisions across the development lifecycle.

From understanding drug behavior and biomarkers to supporting safety and efficacy assessments, these services strengthen decision-making across discovery and development and at Piramal Pharma Solutions, our integrated bioanalytical capabilities enable support from early research through clinical stages.

Read our blog to understand why bioanalytical services are essential in modern drug discovery and development https://lnkd.in/dNG5fJph

Backed by global CDMO capabilities and cross-functional expertise, we enable a connected approach to drug development and manufacturing.​

By bringing together discovery, development, and commercialization, we help simplify complexity, enhance efficiency, and accelerate the path to market for innovative therapies.​

Visit our website to discover how our integrated capabilities support your programs.​ https://lnkd.in/gEEndBM5